亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract A018-PR014: B7-H3-CAR T cells expressing 41BB ligand for pediatric solid tumors: Preliminary results of a phase 1 study

作者
Rebecca Epperly,Teresa Santiago,Selene C. Koo,Lindsay Jones Talbot,Elaine Harstead,Jennifer Wallace,Alexandra Boyd,Jennyfer Bran,Timothy D. Lockey,Catherine Willis,Faizan Ahmad Malik,Ying Li,Leigh Poston,Sarah S Schell,Polly Adams,Manjul Rana,Scott Perry,Jean‐Yves Métais,Deanna M. Langfitt,Salem M. Akel
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (18_Supplement_2): A018-PR014 被引量:1
标识
DOI:10.1158/1538-7445.pediatric25-a018-pr014
摘要

Abstract In this phase 1 dose escalation study (3CAR; NCT04897321) we are evaluating the safety and antitumor activity of a B7-H3-targeted chimeric antigen receptor (B7-H3-CAR) T cell strategy for pediatric patients with relapsed/refractory (r/r) solid tumors. These patients have poor outcomes despite multimodal therapy and need novel therapeutic approaches. B7-H3 is an immunomodulatory protein broadly expressed in solid tumors, with limited expression in healthy tissues, making it an attractive target for immunotherapy. We developed B7-H3-CAR T cells with a CD28.ζ signaling domain, which express 41BB ligand (41BBL) on the cell surface to provide additional costimulation. B7-H3-CAR T cells were generated from CD4+/CD8+ selected autologous apheresis products using a lentiviral vector encoding both the B7-H3-CAR and 41BBL. In this study we are evaluating a single systemic infusion of B7-H3-CAR T cells following fludarabine/cyclophosphamide lymphodepletion in pediatric patients with r/r solid tumors. B7-H3 expression was confirmed by immunohistochemistry on previously obtained tissues using a CLIA-approved assay, with an H-score ≥ 100 considered positive. Evaluated dose levels (DLs) include 3x105 (DL1), 1x106 (DL2), 3x106 (DL3), 1x107 (DL4), and 3x107 (DL5) CAR+ cells/kg. We have enrolled 23 participants for T cell collection, all of whom had successful B7-H3-CAR T cell products manufactured. As of July 2025, 16 participants received B7-H3-CAR T cells (DL1: n=4, DL2: n=3, DL3: n=3, DL4: n=5, DL5: n=1). The median age was 15.1 years (range 4.8-21.3), and participants had a range of solid tumor diagnoses (osteosarcoma n=4, rhabdomyosarcoma n=3, Ewing sarcoma n=2, hepatoblastoma n=2, other soft tissue sarcomas n=5) with a median H-score of 173 (range 110-250). No dose-limiting toxicities were observed among 15 evaluable participants. Nine participants experienced cytokine release syndrome (grade 1: n=7, grade 2: n=2), characterized by early onset fevers starting within 12 hours post-infusion. No participants experienced neurotoxicity. Ten participants underwent tumor biopsy 2 weeks post-infusion. Post-treatment B7-H3 expression was retained in seven of eight quantifiable specimens (median H-score 190, range 30-220). Two participants had local inflammation at superficial tumor sites, with accompanying necrosis on post-treatment biopsies. Imaging-based disease response at 4-6 weeks post-infusion included: 8 stable disease, 7 progressive disease, and 1 not evaluable due to excisional biopsy of a solitary target lesion. B7-H3-CAR T cells were detected in the peripheral blood by qPCR consistently starting with DL2 and were also detected in the peritoneal fluid of a participant with sarcomatosis. B7-H3-CAR T cells can be safely infused in pediatric patients with r/r solid tumors with evidence of homing to tumor sites and antitumor activity. Enrollment is ongoing to establish a recommended CAR T cell dose for further evaluation. Citation Format: Rebecca Epperly, Teresa Santiago, Selene Koo, Lindsay Talbot, Elaine Harstead, Jennifer Wallace, Alexandra Boyd, Jennyfer Bran, Timothy Lockey, Catherine Willis, Faizan Malik, Ying Li, Leigh Poston, Sarah Schell, Polly Adams, Manjul Rana, Scott Perry, Jean-Yves Metais, Deanna Langfitt, Salem Akel, Frank Fazio, Renee Madden, Esther Obeng, Ali Suliman, M Paulina Velasquez, Amr Qudeimat, Caitlin Zebley, Senthil Bhoopalan, Akshay Sharma, Aimee C Talleur, Swati Naik, Brandon M Triplett, Michael Frett, Vinod Maller, Andrew Smith, Michael Bishop, Sara Federico, Alberto Pappo, Andrew Davidoff, Cheng Cheng, Beth McCarville, Stephen Gottschalk, Chris DeRenzo. B7-H3-CAR T cells expressing 41BB ligand for pediatric solid tumors: Preliminary results of a phase 1 study [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2):Abstract nr A018-PR014.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
萧雨墨发布了新的文献求助10
刚刚
大模型的应助被开朗天问采纳,获得10
1秒前
带派不老铁完成签到 ,获得积分10
2秒前
坚强血茗完成签到 ,获得积分10
7秒前
8秒前
11秒前
suyongye完成签到,获得积分10
12秒前
熊猫四海完成签到 ,获得积分10
22秒前
科研通AI6.4的应助被YCLING采纳,获得10
25秒前
玖嬴完成签到,获得积分10
28秒前
Owen的应助被北极幸运星采纳,获得20
29秒前
可靠之玉发布了新的文献求助30
31秒前
helloWorld完成签到,获得积分10
33秒前
34秒前
kiki发布了新的文献求助10
38秒前
39秒前
萧雨墨发布了新的文献求助10
41秒前
42秒前
46秒前
pang完成签到,获得积分10
49秒前
49秒前
努力学习中完成签到,获得积分10
50秒前
余香的应助被萧雨墨采纳,获得10
53秒前
58秒前
YCLING发布了新的文献求助10
58秒前
58秒前
infinity完成签到 ,获得积分10
58秒前
小蘑菇的应助被从容问柳采纳,获得100
59秒前
ubless607给成博的求助进行了留言
1分钟前
666完成签到 ,获得积分10
1分钟前
田様的应助被sissiarno采纳,获得10
1分钟前
共享精神的应助被sissiarno采纳,获得10
1分钟前
余香的应助被sissiarno采纳,获得10
1分钟前
1分钟前
嘻嘻哈哈的应助被sissiarno采纳,获得10
1分钟前
Nole完成签到,获得积分0
1分钟前
CipherSage的应助被sissiarno采纳,获得10
1分钟前
完美世界的应助被sissiarno采纳,获得10
1分钟前
ding的应助被sissiarno采纳,获得10
1分钟前
完美世界的应助被sissiarno采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190049
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851842
捐赠科研通 7788131
什么是DOI,文献DOI怎么找? 3436227
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482768